Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Solid Biosciences (SLDB)
NASDAQ:SLDB
Holding SLDB?
Track your performance easily
SLDB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.63 - $15.05
Previous Close$5.41
Volume403.54K
Average Volume (3M)280.92K
Market Cap
$216.15M
Enterprise Value$69.76M
Total Cash (Recent Filing)$171.12M
Total Debt (Recent Filing)$24.72M
Price to Earnings (P/E)―
Beta2.92
Next Earnings
Mar 12, 2025EPS Estimate
-$0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.04
Shares Outstanding39,954,607
10 Day Avg. Volume345,976
30 Day Avg. Volume280,917
Standard Deviation0.34
R-Squared0.09
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.19
Price to Sales (P/S)408.34
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue139.51
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$18.20Price Target Upside236.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Solid Biosciences News
PremiumCompany Announcements
Solid Biosciences Reports Increased Losses Amid R&D Focus
Bulls Say, Bears Say
Bulls Say
Demand And ExpansionThe demand for SGT-003 has exceeded expectations, leading to plans for trial expansion to Canada and Europe, indicating strong interest from patients and key opinion leaders.
Innovative TechnologySGT-003 utilizes a rationally-designed SLB101 capsid, showing enhanced muscle distribution and reduced liver impact compared to other models, highlighting its advanced technological design.
Safety ProfileSGT-003 has demonstrated a clean safety profile with no serious adverse events in its phase I/II trial, providing reassurance given past concerns with similar treatments.
Bears Say
Durability ConcernsThe long-term durability of Elevidys in DMD patients remains unknown.
Safety ConcernsSafety for the SGT-003 program has been a considerable overhang for investors leading to the current discounted valuation, given the historical difficulties associated with SLDB's first gene therapy candidate, SGT-001.
Uncertainty In Treatment EffectivenessThe jury remains out on whether non-ambulatory patients will materially benefit from Elevidys.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $2.63 and its highest was $15.05 in the past 12 months.
What is Solid Biosciences’s market cap?
Currently, no data Available
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is Mar 12, 2025 which is in 105 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on Nov 06, 2024. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.668 by -$0.122.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -$0.78.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 39,954,605 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.668. Following the earnings report the stock price went down -6.026%.
Which hedge fund is a major shareholder of Solid Biosciences?
Among the largest hedge funds holding Solid Biosciences’s share is Perceptive Advisors LLC. It holds Solid Biosciences’s shares valued at 48M.
---
Solid Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.20 (236.41% Upside)
$18.20 (236.41% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
106.48%
12-Months-Change
Fundamentals
Return on Equity
-65.79%
Trailing 12-Months
Asset Growth
14.67%
Trailing 12-Months
Company Description
Solid Biosciences
Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.
---
SLDB Stock 12 Month Forecast
Average Price Target
$18.20
▲(236.41% Upside)
Technical Analysis
Best Analysts Covering SLDB
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-38.71%
reiterated a buy rating 19 days ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -38.71% per trade.
---